Eric Lefkofsky is the originator and CEO at Tempus, a main supplier of innovation empowered accuracy medication arrangements. He is an establishing accomplice of Lightbank, an endeavor store putting resources into troublesome innovation organizations. Eric Lefkofsky is additionally the prime supporter and Chairman of Lightbank (NASDAQ: GRPN), a worldwide internet business commercial center, and fellow benefactor of Mediaocean. 

 

Mediaocean is the main supplier of coordinated media obtainment innovation; Echo Global Logistics (NASDAQ: ECHO). An innovation empowered transportation and strategies reevaluating firm; InnerWorkings (NASDAQ: INWK). He co-seats the Lefkofsky Family Foundation with his better half, Liz, to propel high-sway drives that upgrade lives in the networks served. Likewise, he is chairman of the Board of Trustees of Chicago’s Steppenwolf Theater Company. 

 

Eric Lefkofsky is an extra teacher at the University of Chicago and the creator of Accelerated Disruption: Understanding the True Speed of Innovation.

Tempus proves various services which include

 

Oncology

Tempus conveys a complete perspective on your patients for oncology suppliers through their set-up of genomic profiling and preliminary matching contributions.

 

Neurology & Psychiatry

For psychological wellness experts, Eric Lefkofsky points out, their pharmacogenomic (PGx) results and quality medication communication data can assist with making accurate medication a reality for every one of your patients.

 

Infectious Disease

Beginning with COVID-19 and stretching out into the expansive scope of viral contaminations, Tempus offers cutting edge testing, cutting edge sequencing, and clinical examination abilities to comprehend and battle these infections.

Tempus is aimed at improving healthcare through AI. Led by Eric Lefkofsky, they have created novel innovations that produce, gather, structure, and examine immense measures of information and converge with the force of AI. They can propel accuracy medication today and, in equal, work with disclosure, improvement and conveyance of ideal therapeutics for later.